Stock Markets March 19, 2026

HHS counselor says candidate pool for CDC leadership is encouraging amid department upheaval

Acting CDC director Jay Bhattacharya steps in as HHS searches for permanent leader after a series of policy changes, firings and legal challenges

By Leila Farooq
HHS counselor says candidate pool for CDC leadership is encouraging amid department upheaval

HHS chief counselor Chris Klomp said he is encouraged by the roster of candidates being considered to lead the Centers for Disease Control and Prevention. Jay Bhattacharya, director of the National Institutes of Health, was named acting CDC director last month amid a wider Health and Human Services reorganization. The agency has experienced budget and staffing cuts and contention over vaccine policy under Health Secretary Robert F. Kennedy Jr., prompting internal departures and a federal court to temporarily block parts of the administration's proposed changes.

Key Points

  • HHS chief counselor Chris Klomp expressed optimism about the pool of candidates to lead the CDC, saying he has met and interviewed multiple prospects and expects to select a strong leader - sectors impacted: public health administration.
  • Jay Bhattacharya, NIH director, was appointed acting CDC director last month amid a departmental shakeup that included the prior acting director Jim O’Neill and the firing of then-director Susan Monarez - sectors impacted: health agencies and regulatory oversight.
  • The CDC has undergone budget cuts, staff reductions and controversial vaccine policy changes under Health Secretary Robert F. Kennedy Jr., and a federal judge has temporarily blocked key parts of the proposed vaccine policy overhaul - sectors impacted: healthcare, vaccine manufacturers, and public health programs.

March 19 - HHS chief counselor Chris Klomp on Thursday described the field of contenders for director of the Centers for Disease Control and Prevention as promising, saying he is upbeat about the prospects for naming a strong permanent leader for the agency.

Jay Bhattacharya, who leads the U.S. National Institutes of Health, was appointed acting CDC director last month as part of a broader realignment within the Department of Health and Human Services ahead of the midterm elections. The shift followed a period of turbulence at the CDC tied to budget reductions, staff cuts and disputes over vaccine policy under Health Secretary Robert F. Kennedy Jr., a longtime anti-vaccine activist.

At a conference held by Stat News, Klomp said he had met and interviewed several candidates and was optimistic about the selection process. He stated, "I’m excited about (the) number of people that I’ve had the privilege to get to meet (and) interview and I’m very optimistic that we will select... an excellent leader for that agency."

Bhattacharya replaced Health and Human Services Deputy Secretary Jim O’Neill, who had been serving as acting CDC director since August. O’Neill took on that acting role after President Trump removed then-director Susan Monarez following her objections to proposed changes in vaccine policy advocated by Kennedy. Monarez’s dismissal prompted the resignations of four senior CDC officials, who cited the administration’s anti-vaccine policies and what they described as misinformation advanced by Kennedy.

During O’Neill’s time as acting director, the CDC made notable policy changes. In January, it removed long-standing broad recommendations for four childhood vaccines. Additionally, the agency last year approved an advisory panel recommendation against early use of the combined measles-mumps-rubella-varicella vaccine.

Legal developments have also affected the administration’s efforts to alter vaccine guidance. A federal judge on Monday issued a temporary block on key components of Kennedy’s initiative to reshape U.S. vaccine policy, including efforts to reduce the routine number of childhood shots and to overhaul the CDC advisory committee on inoculations.

The department’s leadership search continues amid this mix of personnel turnover, policy shifts and judicial scrutiny, leaving the CDC in a period of uncertainty while officials evaluate candidates for the permanent directorship.


Note: The article reports on personnel changes, policy decisions and a pending legal action affecting vaccine recommendations and CDC governance.

Risks

  • Ongoing leadership turnover and internal departures at the CDC could prolong institutional instability and complicate public health coordination - impact on healthcare delivery and public-sector operations.
  • Legal interventions that block proposed policy changes create uncertainty around vaccination recommendations and advisory committee composition - impact on vaccine policy, public health planning, and related market confidence.
  • Policy shifts reducing routine childhood vaccine recommendations and changes to advisory processes could affect vaccine uptake and regulatory guidance - impact on pharmaceutical and biotech firms involved in immunizations and on public health programs.

More from Stock Markets

Regulators Clear Nexstar-Tegna Merger; Deal Closes as Shares Rally Mar 19, 2026 Unilever in advanced talks to fold food arm into McCormick in potential all-stock deal Mar 19, 2026 Super Micro Shares Drop After Co-founder Arrested in Alleged AI Server Export Scheme Mar 19, 2026 Unilever Exploring Sale-and-Combine of Food Unit with McCormick in All-Stock Proposal Mar 19, 2026 DOJ Ends Review of Nexstar’s $3.5 Billion Tegna Acquisition; Legal Challenges Continue Mar 19, 2026